JAMP BILASTINE ORAL SOLUTION DIN 02448262
Health Canada record
| Active ingredient(s) | BILASTINE 2.5 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | |
| Original market date | 21-Apr-2026 |
| Current status date | 21-Apr-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BILASTINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02570521 | APO- BILASTINE | APOTEX INC | Tablet | BILASTINE 20 MG | Approved |
| 02549867 | APO-BILASTINE ORAL SOLUTION | APOTEX INC | Solution | BILASTINE 2.5 MG | Approved |
| 02549875 | APO-BILASTINE ORODISPERSIBLE TABLETS | APOTEX INC | Tablet (Orally-Disintegrating) | BILASTINE 10 MG | Approved |
| 02549883 | APO-BILASTINE TABLETS | APOTEX INC | Tablet | BILASTINE 20 MG | Marketed |
| 02541556 | AURO-BILASTINE | AURO PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02519011 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Solution | BILASTINE 2.5 MG | Marketed |
| 02454130 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02561514 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Solution | BILASTINE 6 MG | Approved |
| 02519038 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Tablet (Orally-Disintegrating) | BILASTINE 10 MG | Marketed |
| 02544369 | GLN-BILASTINE | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | BILASTINE 20 MG | Marketed |
| 02546795 | JAMP BILASTINE | JAMP PHARMA CORPORATION | Tablet | BILASTINE 20 MG | Marketed |
| 02548410 | M-BILASTINE | MANTRA PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02547279 | MAR-BILASTINE | MARCAN PHARMACEUTICALS INC | Tablet | BILASTINE 20 MG | Marketed |
| 02568772 | MINT-BILASTINE | MINT PHARMACEUTICALS INC | Tablet | BILASTINE 20 MG | Approved |
| 02551934 | NRA-BILASTINE | NORA PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02561565 | PMS-BILASTINE | PHARMASCIENCE INC | Tablet | BILASTINE 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35082 | 2025-03-28 | Abbreviated New Drug Submission (ANDS) |
International API supply for BILASTINE
13 active FDA Drug Master Files.
Request a quote for JAMP BILASTINE ORAL SOLUTION